Evidence map›Paper›PMID 41362626›Full record

ArticleiScience2025

Sorafenib as first-line therapy for metastatic uveal melanoma: A multicenter, placebo-controlled randomized discontinuation study (STREAM).

Halime Kalkavan, Max E Scheulen, Eckhart Kämpgen, Ulrich Keilholz, Lucie Heinzerling, Smiths S Lueong, Annalena Hlinka, Tanja Gromke, Sebastian Ochsenreither, Ralf-Axel Hilger and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Halime KalkavanMedical Faculty, University Duisburg-Essen, 45147 Essen, Germany.
Max E ScheulenMedical Faculty, University Duisburg-Essen, 45147 Essen, Germany.
Eckhart KämpgenDepartment of Dermatology, University Hospital Erlangen, 91012 Erlangen, Germany.
Ulrich KeilholzCharité, Comprehensive Cancer Center, 10117 Berlin, Germany.
Lucie HeinzerlingDepartment of Dermatology, University Hospital Erlangen, 91012 Erlangen, Germany.
Smiths S LueongDivision of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK, Partner Site Essen) and German Cancer Research Center, DKFZ, 45147 Heidelberg, Germany.
Annalena HlinkaDepartment of Medical Oncology, West German Cancer Center, University Medicine Essen, 45147 Essen, Germany.
Tanja GromkeDepartment of Medical Oncology, West German Cancer Center, University Medicine Essen, 45147 Essen, Germany.
Sebastian OchsenreitherCharité, Comprehensive Cancer Center, 10117 Berlin, Germany.
Ralf-Axel HilgerDepartment of Medical Oncology, West German Cancer Center, University Medicine Essen, 45147 Essen, Germany.
Matthias GrubertDepartment of Medical Oncology, West German Cancer Center, University Medicine Essen, 45147 Essen, Germany.
Axel WetterDepartment of Radiology, West German Cancer Center, University Medicine Essen, 45147 Essen, Germany.
Nika GuberinaDepartment of Radiotherapy, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
Michael ZeschnigkDepartment of Human Genetics, University Medicine Essen, 45147 Essen, Germany.
Peter FerencyClinAssess, 51379 Leverkusen, Germany.
Swantje HeldClinAssess, 51379 Leverkusen, Germany.
Axel HinkeCCRC - Cancer Clinical Research Consulting, 45147 Düsseldorf, Germany.
Gerold SchulerDepartment of Dermatology, University Hospital Erlangen, 91012 Erlangen, Germany.
Karim Al-GhazzawiDepartment of Ophthalmology, West German Cancer Center, University Medicine Essen, 45147 Essen, Germany.
Norbert BornfeldDepartment of Ophthalmology, West German Cancer Center, University Medicine Essen, 45147 Essen, Germany.
Nikolaos E BechrakisMedical Faculty, University Duisburg-Essen, 45147 Essen, Germany.
Martin SchulerMedical Faculty, University Duisburg-Essen, 45147 Essen, Germany.
Sebastian BauerMedical Faculty, University Duisburg-Essen, 45147 Essen, Germany.
Heike RichlyMedical Faculty, University Duisburg-Essen, 45147 Essen, Germany.
Jens T SivekeMedical Faculty, University Duisburg-Essen, 45147 Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Almost every second patient with uveal melanoma develops metastatic disease, with a usually fatal outcome within one year. The scarcity of broadly applicable systemic therapies further limits patient survival. In this multicenter, placebo-controlled randomized discontinuation phase 2 trial, we evaluated the efficacy of the multi-kinase inhibitor sorafenib in treatment-naïve patients with metastatic uveal melanoma (mUM). After a 56-day

Indexed as

Health sciencesmedical specialtyMedicineoncology

Identifiers

PMID41362626
PMCPMC12682041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.